Antibody specifically binding to ICAM-1 and use thereof
The present invention relates to an anti-ICAM-1 antibody or an antigen-binding fragment thereof that specifically binds to ICAM-1, and the use thereof. Specifically, provided are an anti-ICAM-1 antibody or an antigen-binding fragment thereof, a pharmaceutical composition for regulating differentiation and/or function of dendritic cell, and a pharmaceutical composition for preventing and/or treating immune cell-mediated disease, the composition comprising the antibody or the antigen-binding fragment as an active ingredient.
1. An anti-ICAM-1 antibody or an antigen-binding fragment thereof, comprising the following complementarity determining regions (CDRs):
CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1,
CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2,
CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3,
CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4,
CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and
CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6,
wherein the anti-ICAM-1 antibody or an antigen-binding fragment thereof comprises
a heavy chain variable region comprising the amino acid sequence of SEQ ID NOs: 27; and
a light chain variable region comprising the amino acid sequence of SEQ ID NOs: 35 or 38.
2. The anti-ICAM-1 antibody or the antigen-binding fragment thereof according to claim 1 , wherein the anti-ICAM-1 antibody is a humanized antibody.
3. The anti-ICAM-1 antibody or the antigen-binding fragment thereof according to claim 1 , wherein the antigen-binding fragment is scFv, (scFv) 2, Fab, Fab′, or F (ab′) 2 of the anti-ICAM-1 antibody.
4. A method of treatment of immune cell mediated disease, comprising administering a pharmaceutically effective amount of the anti-ICAM-1 antibody or the antigen-binding fragment thereof according to claim 1 to a subject in need of treatment of the immune cell mediated disease,
wherein the immune cell mediated disease is rheumatoid arthritis or graft versus host disease.
5. A nucleic acid molecule encoding
the amino acid sequence of SEQ ID NO: 27; and
the amino acid sequence of SEQ ID NOs: 35 or 38.
6. A recombinant vector comprising the nucleic acid molecule of claim 5 .
7. A recombinant cell comprising the recombinant vector of claim 6 .
8. A method for producing an anti-ICAM-1 antibody or an antigen-binding fragment thereof, comprising a step of culturing the recombinant cell of claim 7 .
9. A method for detecting ICAM-1, comprising contacting a biological sample with the anti-ICAM-1 antibody or the antigen-binding fragment thereof of claim 1 .
10. A pharmaceutical composition comprising the anti-ICAM-1 antibody or the antigen-binding fragment thereof according to claim 1 .